CA
NZ
UK
AU
IND
US
AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) has spent two years fighting on two fronts: keeping its lead drug Ampligen moving through the clinic, and keeping its shares on a national exchange. As of mid-August 2026, the second fight is over.
Azitra, Inc. (NYSEAMERICAN:AZTR) is built on an unusual idea: engineer Staphylococcus epidermidis, a bacterium that already lives on human skin, so it makes useful proteins where they are needed. For most of its public life it sold that platform as a rare-disease dermatology story.
Curis, Inc. (NASDAQ:CRIS), the Lexington, Massachusetts oncology developer behind emavusertib, has packed a lot into 2026: a January private placement, a 1-for-20Reverse Stock Splitin July, an encouraging brain-lymphoma data update, and now a small, tightly pricedEquityraise.
Femasys Inc. (NASDAQ:FEMY) has spent 2026 running two races at once: proving its women's health devices can sell, and funding the clinical trial that could unlock its biggest market. In early August, the Suwanee, Georgia company made decisive progress on the second front.
HCW Biologics Inc. (NASDAQ:HCWB) has spent 2026 doing two hard things at once: defending its Nasdaq listing and funding its laboratories. By mid-August the Miramar, Florida biotech had made progress on both.
BioVie Inc. (NASDAQ:BIVI) has argued for years that chronic inflammation in the brain is a treatable driver of neurodegenerative disease, not merely a by-product of it. On 6 August 2026 the Carson City, Nevada clinical-stage company produced its cleanest evidence yet: a randomised, placebo-controlled …
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) delivered news on two consecutive days this month. On 6 August 2026 the micro-cap regenerative medicine developer said the U.S. Patent andTrademarkOffice had allowed another patent covering its cell-free approach to type 1 diabetes. A day later it …
GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage cancer company built on one platform. TriKE, short for tri-specific killer engager, is a laboratory-built protein designed to grab a patient's natural killer (NK) cells, hold them against a tumour cell and switch them on.
IN8bio, Inc. (NASDAQ:INAB) is a small New York biotech built around gamma-delta T cells - an uncommon immune cell that attacks tumours without the tissue-matching signals conventional T cells need. It engineers them to survive chemotherapy, a platform called DeltEx DRI, and is testing …
Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) is a Los Angeles clinical-stage oncology company built on one idea: tumours that stop responding to good drugs can be made to respond again. Its lead candidate, ENV-105 (carotuximab), is an antibody targeting CD105, a protein cancer cells display to …
Please wait processing your request...